Immunovant, Inc.
IMVT•NASDAQ•Healthcare•Biotechnology

About Immunovant

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOEric Venker
Founded2018
Employees362
CountryUnited States
Fiscal YearApril - March

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websiteimmunovant.com
Phone917 580 3099
Address
320 West 37th Street, 6th Floor New York, New York 10018 United States

Corporate Identifiers

CIK0001764013
CUSIP45258J102
ISINUS45258J1025
EIN83-2771572
SIC2836

Leadership Team & Key Executives

Dr. Eric Venker M.D., Pharm.D.
Chief Executive Officer and Director
Dr. Frank M. Torti M.B.A., M.D.
Executive Chairperson of the Board
Melanie Gloria B.S.N.
Chief Operating Officer
Christopher A. Van Tuyl Esq., J.D.
Chief Legal Officer and Corporate Secretary
Tiago M. Girao CPA
Chief Financial Officer
Dr. Jay S. Stout M.S., Ph.D.
Chief Technology Officer
Christine Blodgett
Senior Vice President of Human Resources
Andy Deig M.B.A.
Senior Vice President of Strategic Finance
Julie Kirschling
Senior Vice President of Program and Alliance Management
Jody Roth M.S., P.M.P.
Senior Vice President of Regulatory Affairs